Skip to main content

AH: Heidelberg Pharma AG Announces Adjustment of Guidance

Ad hoc announcement - Inside information pursuant to Article 17 MAR

Heidelberg Pharma AG Announces Adjustment of Guidance

Ladenburg, Germany, 4 October 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has adjusted its guidance for the current fiscal year published on 24 March 2022. The license agreement with the strategic partner Huadong Medicine Co., Ltd., Hangzhou, China, and the corresponding license payment increased Heidelberg Pharma’s sales revenue significantly. Development expenses remained below planning due to the later production of intermediate steps for the follow-on candidates. Both factors have an influence on the operating result that will improve and funding requirements for fiscal year 2022 will decrease.

The Heidelberg Pharma Group expects for the financial year 2022 sales and other income between EUR 18.5 million and EUR 20.5 million (previously: EUR 7.5 million to EUR 9.5 million). Operating expenses will range between EUR 35.0 million and EUR 39.0 million (previously: EUR 41.0 million to EUR 45.0 million). Based on these adjustments, an operating result (EBIT) between EUR -16.0 million and EUR -20.0 million is expected (previously: EUR ‑32.5 million to EUR -36.5 million).

For 2022, Heidelberg Pharma anticipates cash requirements of EUR 8.0 million to EUR 11.0 million (previously: EUR 33.0 million to EUR 37.0 million). Monthly cash consumption is expected to range between EUR 0.6 million and EUR 0.9 million per month (previously: EUR 2.8 million and EUR 3.1 million). Based on the existing planning and the capital increase that was closed after the end of the reporting period, the company assumes a financing range until mid-2025.

The Interim Management Statement on the first nine months of 2022 will be published as planned on 13 October 2022.

+++ End of the ad hoc announcement +++